Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of stem cell therapy for diabetes and related conditions, including molecules at the pre-clinical and discovery stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline stem cell therapies for diabetes and related conditions. A few of the key players are Anterogen Co. Ltd., Caladrius Biosciences Inc., ViaCyte Inc., Vertex Pharmaceuticals Inc, among others.

Overview of the stem cell therapy for diabetes and related conditions

Diabetes is a chronic condition associated with high sugar (glucose) levels in the blood, which is owing to the defect in insulin secretion. The prevalence of both type 1 (insulin-dependent diabetes mellitus or juvenile onset) and type 2 (non-insulin-dependent diabetes mellitus or adult-onset diabetes) is increasing globally. However, type 2 diabetes, is the more common type. According to the Centers for Disease Control and Prevention (CDC), in 2018, 34.2 million people belonging to all age groups, or 10.5% of the US population, had diabetes. Out of this, 26.9 million people, or 8.2% of the US population, had diabetes that had been diagnosed. According to the IDF Diabetes Atlas, an estimated 59 million adults (20-79 years) were living with diabetes in the IDF Europe Region in 2019. On the other hand, other Asian countries, such as Japan, Sri Lanka, Indonesia, Thailand, and Vietnam, have also witnessed a significant increase in the prevalence of diabetes in the past decade.

According to this pipeline analysis report, most of the molecules in the pipeline are being developed for monotherapy and combination therapy. Over 54% of the drug development is in the pre-clinical stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of stem cell therapy for diabetes and related conditions. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the stem cell therapy molecules for diabetes discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Anterogen Co. Ltd.
• AgeX Therapeutics Inc.
• Caladrius Biosciences Inc.

Therapeutic assessment of the stem cell therapy for diabetes and related conditions route of administration

• Intravenous
• Intramuscular
• Topical
• Others

The intravenous route of administration (ROA) involves drug delivery through the subcutis. In the current pipeline, four molecules are administered through this route. On the other hand, intramuscular drug delivery has just one molecule currently being administered.

Therapeutic assessment of the stem cell therapy for diabetes and related conditions by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, all the molecules that are currently being developed as stem cell therapy for diabetes and related conditions are as monotherapy drugs. About 20 monotherapy molecules are under development. In addition to the active molecules, there are also a number of pipeline products that have been either discontinued from development or are currently dormant.

Key questions answered in the report include

• What are the stem cell therapy molecules in the various development stages for diabetes and related conditions?
• What are the companies that are currently involved in the development of stem cell therapy for diabetes and related conditions?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirements. Get in touch